Antifracture Efficacy of 5- or 10-Yearly Zoledronate in Women Aged 50 to 60 Years: Secondary Analyses of a Randomized Trial
Fracture reductions with single-dose or 5-yearly zol appear greater during years 5 to 10 than years 0 to 5. The risk reductions are broadly consistent across this cohort and independent of baseline or change in BMD. This suggests that routine BMD monitoring may not be necessary for low-risk women considering the option of less frequent zol for long-term fracture risk reduction.
Authors
- Borislav Mihov (ORCID: https://orcid.org/0000-0002-0147-0595)
- Veronica Pinel
- Anna Mellar (ORCID: https://orcid.org/0000-0002-8641-6968)
- Andrew B. Grey (ORCID: https://orcid.org/0000-0002-7803-0096)
- Greg D. Gamble (ORCID: https://orcid.org/0000-0003-0412-3203)
- Chiara Gasteiger (ORCID: https://orcid.org/0000-0002-0597-2349)
- Ian R. Reid (ORCID: https://orcid.org/0000-0001-6021-5458)
- Anne Horne (ORCID: https://orcid.org/0000-0003-2783-7452)
- Mark J Bolland (ORCID: https://orcid.org/0000-0003-0465-2674)
- Sonja Bastin (ORCID: https://orcid.org/0009-0003-6750-8140)
- Zaynah Nisa
Institutions
- University of Auckland (NZ)
- Starship Children's Health (NZ)
- Stanford University (US)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1210/clinem/dgaf569
- Citations
- 1
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Health Research Council of New Zealand